STELIOS PAPADOPOULOS - 26 Feb 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Director
Signature
/s/ Jeffrey Rona, Attorney-in-Fact
Issuer symbol
OVID
Transactions as of
26 Feb 2026
Net transactions value
$0
Form type
4
Filing time
02 Mar 2026, 16:30:20 UTC
Previous filing
13 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PAPADOPOULOS STELIOS Director C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, 14TH FLOOR, NEW YORK /s/ Jeffrey Rona, Attorney-in-Fact 02 Mar 2026 0001202098

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Employee Stock Option (Right to Buy) Award $0 +65,000 $0.000000 65,000 26 Feb 2026 Common Stock 65,000 $1.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.